Purpose: The purpose of the study is to determine if the use of a proton pump inhibitor (PPI) is associated with an increased fracture risk, as some prior studies have suggested.
| INTRODUCTION
Proton pump inhibitors (PPIs) are used to treat gastroesophageal reflux (GERD) and gastric or duodenal ulcers. 1 In the USA, 6 PPIs are currently available (Supplemental Table 1 ). About 30% of the adult population in the US utilizes PPIs, making them among the most commonly used drugs. 2 Not only has PPI use increased since omeprazole became available over the counter (OTC) in 2003, but in recent years, the duration of prescription use has also increased, resulting in numerous people taking these medications for several years or more. 3 Fractures are an important outcome for older adults because these events often give rise to severe complications or mortality. [4] [5] [6] It has been hypothesized that the use of PPIs increases the risk of fractures, 7 as these medications target hydrogen and potassium ATPase pumps of gastric parietal cells, resulting in decreased stomach acidity. PPIs are thought to diminish bone mineral density (BMD) by effects on stomach acidity and the consequent reduction of calcium absorption, which might make someone more susceptible to fractures. To date, however, studies have not documented these changes in BMD among PPI users to support this hypothesis. 7, 8 In addition to mechanistic uncertainties, the presence and magnitude of an association between PPI use and fractures in the epidemiologic literature is inconsistent, with some studies reporting an increased risk, 2,3,9-11 while others report no associations 12 or associations limited to only a subset of high-risk patients 13 or a subset of fracture sites. 7, 8 In studies observing an increased risk of fractures, many found associations with PPI use equivalent to 1 year or less. 9, [13] [14] [15] However, the mechanism described previously would have a long induction period before clinically measurable effects on BMD or fracture risk would appear, making the presence of a causal association with rapid onset implausible unless by way of another mechanism.
The reasons for discrepant results among epidemiologic studies are not clear. A limitation of prior longitudinal studies is the reliance on administrative, claims-based data sources only. This type of data does not allow for adequate control of likely confounders such as concomitant medication use, exercise, body mass index (BMI), and tobacco use. Furthermore, the impact of cumulative dose rather than a binary variable for medication exposure on fracture risk has not been well evaluated.
The primary aim of this study was to examine the association between PPI use and the incidence of fractures. To address limitations of prior studies, the present study draws on data from a prospective cohort study, which allows for detailed measurement of PPI exposure, health behaviors, functional status measures, and medical histories of study participants which greatly enhances the ability to control for important confounding factors.
| METHODS
This study utilized data from a prospective cohort study of older adults enrolled in Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system with approximately 600,000 members residing in the Pacific Northwest. The exposure of interest was cumulative use of PPI medications measured from electronic pharmacy data, and the outcome of interest was a fracture of the hip, forearm, humerus, clavicle or scapula, rib or sternum, tibia or fibula, or ankle, ascertained from electronic diagnosis data including emergency department, inpatient, and outpatient records.
| OVERVIEW AND SETTING
Participants were part of the Adult Changes in Thought (ACT) cohort, a prospective cohort study at KPWA. ACT study methods have been described in detail elsewhere. 16 A brief description of study methods follows; study participants were recruited from a random sample of Seattle-area members of KPWA who were 65 or older. Participants were required to be community-dwelling and cognitively intact at study entry. The original cohort of 2581 men and women was enrolled between 1994 and 1996, followed by an additional 811 participants who were enrolled between 2000 and 2003 (the "expansion cohort").
Then, in 2004, the study began continuous enrollment (n = 1555 available for this study) to replace those who died or dropped out, resulting in a total of 4947 participants as of the end of April, 2014, who were available for this study. 
| EXPOSURE MEASUREMENT
The KPWA pharmacy database includes all prescriptions dispensed from KPWA pharmacies from March, 1977 to present, including drug name, strength, and quantity. In prior studies, 96% of older KPWA members have reported filling all or most of their prescriptions at a KPWA pharmacy. 17 The exposure of interest was cumulative use of any PPI medication calculated by first converting each prescription to
KEY POINTS
• Previous studies have inconsistently reported an increase in fracture risk among users of proton pump inhibitors.
• Fractures are a critically important outcome among older adults because of their association with declining health.
• Proton pump inhibitors are widely used medications with approximately a third of the adult population using these medications.
• In addition to pharmacy data, self-reported medication use was collected at ACT follow-up interviews every 2 years, including information about any OTC medications used, allowing us to identify participants reporting OTC PPI use, which otherwise would not have been identified.
| ASCERTAINMENT OF FRACTURE
All participants who experienced a fracture of the hip, forearm, humerus, clavicle or scapula, rib or sternum, tibia or fibula, or ankle during follow-up were identified. Vertebral fractures were not included in the outcome definition because estimates show that up to 75% of individuals with vertebral fracture may not seek medical attention. 21 Because of this, it is difficult to know when they occur. We did not limit our outcomes to study only fractures because of limited trauma, as work has shown that high-trauma fractures are associated with low bone mineral density and therefore a higher risk of subsequent fracture particularly among older adult populations. 22 Ankle fractures, though sometimes not considered in studies of osteoporotic fractures, were included here because these fractures have features of osteoporotic fractures that are subject to age and sex-dependent low bone attenuation. 23 We chose these fracture sites in part based on results from a prior validation study at KPWA (unpublished). That study examined women aged 45 to 59 enrolled in KPWA, with an inpatient or outpatient International Classification of Diseases, Ninth Revision (ICD-9) code (n = 3178) for fracture in their chart and age-matched controls (n = 4374). Data were collected through interviews and detailed medical record reviews. Overall, ICD-9 codes for osteoporotic fractures (included fractures of the forearm, humerus, rib, sternum, scapula, clavicle, vertebra, pelvis, hip, femur, tibia/fibula, and ankle) had a positive predictive value of approximately 80%. Furthermore, the sensitivity of ICD-9 codes was 83.7%, and specificity was 98.7%. The authors concluded that ICD-9 codes can be used to identify fractures in adults using large datasets because of the high sensitivity and specificity, but there will be some misclassification with fractures of the rib, spine, or a nonspecific location. In the present study, fractures were identified using electronic health data by searching for 1 or more relevant ICD-9 diagnosis codes 807, 810 to 814, 820, 823, and 824 in inpatient, outpatient, or emergency department records.
| POTENTIAL CONFOUNDERS
At study baseline and follow-up visits, information on covariates was collected. Demographic factors included age, sex, and race. Medical history included self-reported data on epilepsy, vision problems, stroke, congestive heart failure, and coronary heart disease (CHD), with CHD defined as a self-reported history of myocardial infarction, angina, cor- We conducted additional analyses to evaluate the possible influence of age (>75 versus ≤75) or sex on the association between PPI use and fracture risk. For these analyses, we estimated 2 additional adjusted models, one including an interaction between age and exposure and another with an interaction between sex and exposure. Lastly, we tested the effect that recency of PPI use might have on fracture risk.
For this recency analysis, the sample was restricted to those who were exposed to PPIs during the study period. Recent users were defined as those who were exposed to PPIs during the year prior to an event, and distant users were those who had not been exposed to PPIs in the year prior to an event. We also tested whether there was evidence of an interaction between cumulative exposure and recency of use. In addition, we conducted a post hoc sensitivity analysis examining current use, which we defined as a fill for a PPI medication with the past 30 days.
Complete case analysis methods were used. The assumption of proportionality of hazards was tested by examining Schoenfeld residuals.
All analyses were performed using STATA version 13. Before beginning the study, we conducted power calculations which showed that we would be powered to detect a hazard ratio of 1.2 or greater for the association between binary PPI use (yes/no) and fracture risk in our cohort.
| RESULTS
There were a total of 4438 participants with a median age of 74.0 years (interquartile range [IQR] 69.8-79.5) at study entry, 58% of whom were women. Table 1 provides baseline characteristics of all study participants. Additionally, Table 2 group was 1.08 (95% CI 0.83-1.40) for light users, 1.31 (95% CI 0.86-1.95) for moderate users, and 0.95 (95% CI 0.68-1.34) for heavy users (Table 3) . Results from the fully adjusted model are available in supplementary material (Supplemental Table 2 ).
There was no evidence of an association between PPI use and fracture in subgroups defined by age (>75 years compared to ≤75 years) or sex with P values of 0.09 and 0.46, for the difference in relative risks by age and sex, respectively (data not shown). In the recency analysis, we found no evidence of differing fracture risk between these groups, with an aHR of 1.14 (95% CI 0.91-1.42) characterizing the risk of fracture for those with recent exposure within the past year to those with distant use. Furthermore, no interaction was found between recency and cumulative exposure (P = 0.25). We also found no evidence of a difference of risk in our current use analysis, which examined the risk of fracture among those having a fill for a PPI medication within the past 30 days compared to those without Restricted to PPI users only and compares those with recent use (use within prior year) to the reference group of distant users.
In conclusion, in contrast to some prior studies, we observed no appreciable association of PPI use with risk of fracture. 
